No Data
Guangxi Wuzhou Zhongheng Group (600252.SH) has appointed Wang Hairun as the chief legal counsel.
Guangxi Wuzhou Zhongheng Group (600252.SH) announced that, given that Wang Xiangyong has resigned from the position of general legal advisor of the company, in order to strengthen the company...
Guangxi Wuzhou Zhongheng Group (600252.SH): The public solicitation of some shares of Chongqing Lummy Pharmaceutical is temporarily suspended.
On December 27, Gala Exchange reported that Guangxi Wuzhou Zhongheng Group (600252.SH) announced that on December 13, 2024, it disclosed the "Announcement on the Public Collection of Buyers for the Proposed Agreement Transfer of Shares of Chongqing Lummy Pharmaceutical Co., Ltd." on the Shanghai Stock Exchange website. The company plans to transfer 247,426,064 unrestricted circulating A-share stocks of Chongqing Lummy Pharmaceutical Co., Ltd. (referred to as "Lummy Pharmaceutical"), which accounts for 23.43% of Lummy Pharmaceutical's total share capital, through a public collection of buyers.
Guangxi Wuzhou Zhongheng Group (600252.SH): A subsidiary plans to participate in the establishment of FOSUN PHARMA (Nanning) Co., Ltd.
Gelonghui reported on December 27 that Guangxi Wuzhou Zhongheng Group (600252.SH) announced that in order to meet the needs of the company's Business development, further expand the layout of the overseas market Business and enhance comprehensive competitiveness, Guangxi Wuzhou Zhongheng Group's wholly-owned subsidiary Zhongheng Yixin plans to establish a joint venture with the wholly-owned subsidiary of FOSUN PHARMA, Shanghai FOSUN PHARMA Industrial Development Co., Ltd. (referred to as "FOSUN Industrial Company"), and Nanning Industry Investment Unified Investment Group Co., Ltd. (referred to as "Unified Investment Group"). The registered capital of the joint venture is 100 million yuan, of which FOSUN Industrial Company contributes 5,100.
Does Guangxi Wuzhou Zhongheng GroupLtd (SHSE:600252) Have A Healthy Balance Sheet?
Chongqing Lummy Pharmaceutical (300006.SZ) controlling shareholder Guangxi Wuzhou Zhongheng Group plans to publicly solicit agreements for the transfer of 23.43% of its shares.
Chongqing Lummy Pharmaceutical (300006.SZ) announced that the company's controlling shareholder Guangxi Wuzhou Zhongheng Group Co., Ltd. (abbreviated as...
Guangxi Wuzhou Zhongheng Group (600252.SH): Plans to transfer shares of Chongqing Lummy Pharmaceutical and has obtained approval from the Guangxi State-owned Assets Supervision and Administration Commission.
On December 12, according to Gelonghui, Guangxi Wuzhou Zhongheng Group (600252.SH) announced that on December 12, 2024, the company received a notice from its controlling shareholder, Guangxi Investment Group Co., Ltd. The plan to publicly solicit transferees for transferring the company's 23.43% stake in Chongqing Lummy Pharmaceutical has been approved by the State-owned Assets Supervision and Administration Commission of the People's Government of Guangxi Zhuang Autonomous Region, and in principle, Guangxi Wuzhou Zhongheng Group has publicly solicited potential transferees for its 247,426,064 A-share shares in Chongqing Lummy Pharmaceutical.
Lacklustre Performance Is Driving Guangxi Wuzhou Zhongheng Group Co.,Ltd's (SHSE:600252) Low P/S
No Data
